Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021

Regina Selb; Susanne Buder; Sandra Dudareva; Thalea Tamminga; Viviane Bremer; Sebastian Banhart; Dagmar Heuer; Klaus Jansen

doi:10.2807/1560-7917.ES.2021.26.31.2100616

Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021

Regina Selb (Corresponding Author), Susanne Buder, Sandra Dudareva, Thalea Tamminga, Viviane Bremer, Sebastian Banhart, Dagmar Heuer, Klaus Jansen

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.

Original language	English
Article number	2100616
Journal	EUROSURVEILLANCE
Volume	26
Issue number	31
DOIs	https://doi.org/10.2807/1560-7917.ES.2021.26.31.2100616
Publication status	Published - 5 Aug 2021
Externally published	Yes

Keywords*

Neisseria gonorrhoeae
Azithromycin
Germany
antimicrobial susceptibility testing

Field of Science*

3.3 Health sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2021.26.31.2100616Licence: CC BY

Cite this

@article{2562ccb172b947b5a8b011515d3892f7,

title = "Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021",

abstract = "We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.",

keywords = "Neisseria gonorrhoeae, Azithromycin, Germany, antimicrobial susceptibility testing",

author = "Regina Selb and Susanne Buder and Sandra Dudareva and Thalea Tamminga and Viviane Bremer and Sebastian Banhart and Dagmar Heuer and Klaus Jansen",

year = "2021",

month = aug,

day = "5",

doi = "10.2807/1560-7917.ES.2021.26.31.2100616",

language = "English",

volume = "26",

journal = "EUROSURVEILLANCE",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "31",

}

TY - JOUR

T1 - Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021

AU - Selb, Regina

AU - Buder, Susanne

AU - Dudareva, Sandra

AU - Tamminga, Thalea

AU - Bremer, Viviane

AU - Banhart, Sebastian

AU - Heuer, Dagmar

AU - Jansen, Klaus

PY - 2021/8/5

Y1 - 2021/8/5

N2 - We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.

AB - We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.

KW - Neisseria gonorrhoeae

KW - Azithromycin

KW - Germany

KW - antimicrobial susceptibility testing

UR - http://www.scopus.com/inward/record.url?scp=85113301551&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2021.26.31.2100616

DO - 10.2807/1560-7917.ES.2021.26.31.2100616

M3 - Article

C2 - 34355690

AN - SCOPUS:85113301551

SN - 1025-496X

VL - 26

JO - EUROSURVEILLANCE

JF - EUROSURVEILLANCE

IS - 31

M1 - 2100616

ER -

Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this